<DOC>
<DOCNO>EP-0620225</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Cephalosporin derivatives
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D50118	A61K31546	A61P3100	C07D50124	A61P3104	A61K31545	A61K31545	C07D50156	C07D50148	C07D50116	A61K31546	C07D50100	C07D50100	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	A61K	A61P	C07D	A61P	A61K	A61K	C07D	C07D	C07D	A61K	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D501	A61K31	A61P31	C07D501	A61P31	A61K31	A61K31	C07D501	C07D501	C07D501	A61K31	C07D501	C07D501	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Cephalosporin derivatives of the general formula 

wherein 

R¹
is an acyl group derived from a carboxylic acid; 
R²
is hydrogen, hydroxy, lower alkyl-Q
m
, cycloalkyl, lower alkoxy, 
lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl-Q
m
, aryl-Q
m
, 
aryloxy, aralkoxy or a heterocyclic ring, the lower alkyl, cycloalkyl, 

lower alkoxy, lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl, 
aryl, aryloxy, aralkoxy and the heterocyclic ring being 

unsubstituted or substituted with at least one group selected from 
carboxy, amino, nitro, cyano, lower alkyl, lower alkoxy, hydroxy, 

halogen, -CONR⁴R⁵, -N(R⁵)COOR⁹, R⁵CO-, R⁵OCO- or R⁵COO- where 
R⁴ is hydrogen, lower alkyl, or cycloalkyl; R⁵ is hydrogen or 

lower alkyl; R⁹ is hydrogen, lower alkyl, lower alkenyl or a 
carboxylic acid protecting group; 
Q
is -CO- or -SO₂-; 
m
is 0 or 1; 
n
is 0, 1 or 2; 
 
as well as readily hydrolyzable esters thereof, pharmaceutically acceptable 

salts of said compounds and hydrates of the compounds of formula I and of 
their esters and salts. 
The products are antibacterially active. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
BASILEA PHARMACEUTICA AG
</APPLICANT-NAME>
<APPLICANT-NAME>
BASILEA PHARMACEUTICA AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ANGEHRN PETER
</INVENTOR-NAME>
<INVENTOR-NAME>
WEI CHUNG-CHEN
</INVENTOR-NAME>
<INVENTOR-NAME>
ANGEHRN, PETER
</INVENTOR-NAME>
<INVENTOR-NAME>
WEI, CHUNG-CHEN
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The present invention relates to cephalosporin derivatives of the general
formula

   wherein
R2is hydrogen, hydroxy, C1-C8-alkyl-Qm, C3-C7-cycloalkyl, C1-C8-alkoxy,
C2-C8-alkenyl, C3-C9-cycloalkenyl, C2-C8-alkynyl, phenyl-C1-C8-alkyl-Qm,
phenyl-Qm, phenoxy, phenyl-C1-C8-alkoxy or an unsaturated or
saturated, unsubstituted or substituted 5-, 6- or 7-membered
heterocyclic ring containing at least one hetero atom selected from the
group consisting of oxygen, nitrogen or sulfur, the C1-C8-alkyl, C3-C7-cycloalkyl,
C1-C8-alkoxy, C2-C8-alkenyl, C3-C9-cycloalkenyl, C2-C8-alkynyl,
phenyl-C1-C8-alkyl, phenyl, phenoxy, phenyl-C1-C8-alkoxy and
the heterocyclic ring being unsubstituted or substituted with at least
one group selected from carboxy, amino, nitro, cyano, C1-C8-alkyl, C1-C8-alkoxy,
hydroxy, halogen, -CONR4R5, -N(R5)COOR9, R5CO-, R5OCO-or
R5COO- where R4 is hydrogen, C1-C8-alkyl, or C3-C7-cycloalkyl; R5 is
hydrogen or C1-C8-alkyl; R9 is C1-C8-alkyl, C2-C8-alkenyl, benzhydryl,
p-nitrobenzyl or p-methoxybenzyl;Qis -CO- or -SO2-;mis 0 or 1; R3is hydrogen, C1-C8-alkyl, phenyl- C1-C8-alkenyl, C3-C7-cycloalkyl,
R5CO- or -C(R7R8)CO2R9'; where R7 and R8 are each independently
hydrogen or C1-C8-alkyl, or R7 and R8 taken together form a C3-C7-cycloalkyl
group; R9 is hydrogen or R9 and R4, R5 and R9 are as under
R2;
as well as readily hydrolyzable esters thereof, pharmaceutically
acceptable salts of said compounds and hydrates of the compounds of
formula I and of their esters and salts.In above compounds of formula I the substituent in position 3 can be
present
in the E-form:

or in the Z-form:
In a particular embodiment of the compounds of formula I n is 0. In
another particular embodiment of the compounds of formula I R2 is C1-C8-lower
alkyl-Q, where Q is -CO- or -SO2-. In yet another embodiment of the
compounds of formula I R2 is propargyl (2-propynyl), cyanomethyl, cyanoethyl
or cyclopropylmethyl. In a further embodiment of the compounds of formula I
R2 is 6-methoxy-pyridin-3-yl, 5-methyl-isoxazol-3-yl, 2-oxo-oxazolidin-3-yl or
1,1-dioxo-tetrahydrothien-3-yl.R3 is preferably hydrogen, C1-C8-alkyl, C3-C7-cycloalkyl or
C(R7R8)CO2R9', particularly hydrogen.Preferred compounds of formula I are such where R2 is hydrogen,
cycloalkyl, C1-C8-alkyl which is unsubstituted or substituted with halogen, C1-C8-
alkoxy or phenyl which is unsubstituted or substituted with at least one of
C1-C8- alkoxy or halogen. Further preferred compounds of formula I are such where R2 is any of
phenyl, 4-methoxyphenyl, 2,2,2-trifluoroethyl,
</DESCRIPTION>
<CLAIMS>
Cephalosporin derivatives of the general formula


wherein

R
2
is hydrogen, hydroxy, C
1
-C
8
-alkyl-Q
m
, C
3
-C
7
-cycloalkyl, C
1
-C
8
-alkoxy,
C
2
-C
8
-alkenyl, C
3
-C
9
-cycloalkenyl, C
2
-C
8
-alkynyl, phenyl-C
1
-C
8
-alkyl-Q
m
,
phenyl-Q
m
, phenoxy, phenyl-C
1
-C
8
-alkoxy or an unsaturated or
saturated, unsubstituted or substituted 5-, 6- or 7-membered

heterocyclic ring containing at least one hetero atom selected from the
group consisting of oxygen, nitrogen or sulfur, the C
1
-C
8
-alkyl, C
3
-C
7
-cycloalkyl,
C
1
-C
8
-alkoxy, C
2
-C
8
-alkenyl, C
3
-C
9
-cycloalkenyl, C
2
-C
8
-alkynyl,
phenyl-C
1
-C
8
-alkyl, phenyl, phenoxy, phenyl-C
1
-C
8
-alkoxy and
the heterocyclic ring being unsubstituted or substituted with at least

one group selected from carboxy, amino, nitro, cyano, C
1
-C
8
-alkyl, C
1
-C
8
-alkoxy,
hydroxy, halogen, -CONR
4
R
5
, -N(R
5
)COOR
9
, R
5
CO-, R
5
OCO-
or R
5
COO- where R
4
 is hydrogen, C
1
-C
8
-alkyl, or C
3
-C
7
-cycloalkyl; R
5
 is
hydrogen or C
1
-C
8
-alkyl; R
9
 is C
1
-C
8
-alkyl, C
2
-C
8
-alkenyl, benzhydryl,
p-nitrobenzyl or p-methoxybenzyl;
Q
is -CO- or -SO
2
-;
m
is 0 or 1;
R
3
is hydrogen, C
1
-C
8
-alkyl, phenyl- C
1
-C
8
-alkenyl, C
3
-C
7
-cycloalkyl,
R
5
CO- or -C(R
7
R
8
)CO
2
R
9'
; where R
7
 and R
8
 are each independently
hydrogen or C
1
-C
8
-alkyl, or R
7
 and R
8
 taken together form a C
3
-C
7
-cycloalkyl
group; R
9'
 is hydrogen or R
9
 and R
4
, R
5
 and R
9
 are as under
R
2
;
 
   as well as readily hydrolyzable esters thereof, pharmaceutically

acceptable salts of said compounds and hydrates of the compounds of
formula I and of their esters and salts.
Compounds of claim 1, wherein R
3
 is hydrogen, C
1
-C
8-
alkyl, C
3-7
-cycloalkyl
or C(R
7
R
8
)CO
2
R
9'
.
Compounds of claim 2, wherein R
3
 is hydrogen.
Compounds of any one of claims 1-3, wherein R
2
 is hydrogen, C
3-7
-cycloalkyl,
C
1
-C
8-
alkyl which is unsubstituted or substituted with halogen, C
1
-C
8
-alkoxy
or phenyl which is unsubstituted or substituted with at least one of

C
1
-C
8
-alkoxy or halogen.
Compounds of any one of claims 1-3, wherein R
2
 is any of phenyl, 4-methoxyphenyl,
2,2,2-trifluoroethyl, 2-fluoroethyl, cyclopropyl, 3-pyridinyl,

allyl, cyanomethyl, cyclopropylmethyl, 2-propynyl and 2-pyrazinyl.
Compounds of any one of claims 1-5 with the 3-substituent in the
E-form.
The compound of claims 5 and 6


   [6R-[3(E),6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-3-[[1-cyclopropyl-2-oxo-3-pyrrolidinylidene]
methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic
acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
The compound of claims 5 and 6 


   [6R-[3(E),6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-3-[[1-(2-fluoroethyl)-2-oxo-3-pyrrolid
inylidene]methyl]
-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic

acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
The compound of claims 5 and 6


   [6R-[3(E),6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-3-[[1-(2,2,2-trifluoroethyl)-2-oxo-3-pyrrolidinylidene]
methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic
acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
The compound of claims 5 and 6


   [6R-[3(E),6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-3-[[2-oxo-1-phenyl-3-pyrrolidinylidene]
methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic
acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of 
said compound and salts.
The compound of claims 5 and 6


   [6R-[3(E),6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-3-[[1-(4-methoxyphenyl)-2-oxo-3-pyrrolidinylidene]
methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic
acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
The compound of claims 5 and 6


   [6R-[3(E),6α,7
β
(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-8-oxo-3-[[2-oxo-1-(3-pyridinyl)-3-pyrrolidinylidene]
methyl]-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic
acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
The compound of claims 5 and 6


   [6R-[3(E),6α,7β(Z)]]-3-[[1-allyl-2-oxo-3-pyrrolidinylidene]
methyl]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic 
acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
The compound of claims 5 and 6


   [6R-[3(E),6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-3-

[[1-cyanomethyl-2-oxo-3-pyrrolidinylidene]methyl]
-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic

acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
The compound of claims 5 and 6


   [6R-[3(E),6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-3-[[1-cyclopropylmethyl-2-oxo-3-pyrrolidinylidene]
methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic
acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
The compound of claims 5 and 6 


   (6R-[3(E),6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-8-oxo-3-[[2-oxo-1-(2-propynyl)-3-pyrrolidinylidene]
methyl]-5-thia-1-azabicyclo[4.2.0]
-oct-2-ene-2-carboxylic
acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
The compound of claims 5 and 6


   [6R-[3(E),6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]
-amino]-8-oxo-3-[[2-oxo-1-(2-pyrazinyl)-3-pyrrolidinylidene]
methyl]-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic
acid,

as well as pharmaceutically acceptable salts of this compound and hydrates of
said compound and salts.
Compounds of claim 1, wherein R
2
 is C
1
-C
8
-alkyl-Q, phenyl-C
1
-C
8
-alkyl-Q
or phenyl-Q, where Q is -CO- or -SO
2
-.
Compounds of claim 1, wherein R
2
 is 2-propynyl, cyanomethyl,
cyanoethyl or cyclopropylmethyl.
Compounds of claim 1, wherein R
2
 is 6-methoxy-pyridin-3-yl,
5-methyl-isoxazol-3-yl, 2-oxo-oxazolidin-3-yl or 1,1-dioxo-tetrahydrothien-3-yl.
Compounds of the formula 


   in which R
2
 is defined above,

or esters or salts thereof.
Compounds of the formula


   in which R
2
 is defined above, p is 0 or 1 and R
10
 is an amino
protecting group selected from t-butoxycarbonyl, trichloroethoxycarbonyl,

p-nitrobenzyloxycarbonyl, benzyloxycarbonyl, trityl,
benzhydryl, chloroacetyl, bromoacetyl, iodoacetyl and

trifluoroacetyl,

or esters or salts thereof.
Compounds of the formula


   in which R
h
 is hydrogen or a carboxy protecting group, R
f
 is as R
1

and R
g
 is as R
2
 with the proviso that at least one of the following
provisions is fulfilled:


(i) R
h
 is a carboxylic acid protecting group,
(ii) R
f
 is a residue defined under R
1
 having nitro, protected amino, 
protected hydroxy and/or protected carboxylic group(s),
(iii) R
g
 is a residue defined under R
2
 having nitro, protected amino,
protected hydroxy and/or protected carboxylic group(s),

or salts thereof,

amino protecting groups being selected from t-butoxycarbonyl, trichloroethoxycarbonyl,
p-nitrobenzyloxycarbonyl, benzyloxycarbonyl, trityl,

benzhydryl, chloroacetyl, bromoacetyl, iodoacetyl and trifluoroacetyl; hydroxy
protecting groups being selected from trityl, acetyl, tetrahydropyranyl, benzyl

and p-nitrobenzyl; and carboxy protecting groups being selected from
benzhydryl, t-butyl, p-nitrobenzyl, p-methoxybenzyl and allyl.
Compounds as in any one of claims 1-20 as pharmaceutically active
substances for the treatment and prophylaxis of illnesses.
Compounds as in any one of claims 1-20 as pharmaceutically active
substances for the treatment and prophylaxis of infectious diseases.
Process for the manufacture of the compounds according to any one of
claims 1-20, which process comprises


(a) treating a compound having the formula


   in which R
2
 is defined above,

or an ester or salt thereof, with acylating agents corresponding to the acyl
group



or
(b) for the manufacture of a compound of formula I in which R
1
 and/or R
2
 
may contain free amino, hydroxy or carboxylic group(s) cleaving off the amino,

hydroxy and/or carboxy protecting group(s) or reducing a nitro group to amino
in a compound having the formula



   in which R
h
 is hydrogen or a carboxy protecting group, R
f
 is as R
1

and R
g
 is as R
2
 with the proviso that at least one of the following
provisions is fulfilled:


(i) R
h
 is a carboxylic acid protecting group,
(ii) R
f
 is a residue


in which R is an amino
protecting group and R
3f
 is as R
3
 but has nitro, protected amino,
protected hydroxy and/or protected carboxylic group(s),
(iii) R
g
 is a residue defined under R
2
 having nitro, protected amino,
protected hydroxy and/or protected carboxylic group(s),

or a salt thereof, or
(c) for the manufacture of a readily hydrolyzable ester of a compound of
formula I subjecting a carboxylic acid of formula I to a corresponding

esterification, or
(d) for the manufacture of salts or hydrates of a compound of formula I or
hydrates of said salts converting a compound of formula I into a salt or

hydrate or into a hydrate of said salts, amino, hydroxy and carboxy protecting
groups being defined as in claim 23.
A pharmaceutical preparation containing a compound according to
any one of claims 1-20. 
A pharmaceutical preparation for the treatment and prophylaxis of
infectious diseases containing a compound according to any one of claims 1-20.
The use of the compounds according to any one of claims 1-20 for the
manufacture of medicaments for the treatment and prophylaxis of infectious

diseases.
</CLAIMS>
</TEXT>
</DOC>
